Tymlos 80 MCG dose pen injectr 1.56ML
Ended Awarded
- Contract number
- SPE2DB26FNMNB
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $6,693
Award facts
- Contract value 100% obligated
- $6,692.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $6,692.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for TYMLOS 80 MCG Dose Pen Injectr 1.56ML. This firm fixed-price delivery order, issued on October 23, 2025, with an ultimate completion date of October 24, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that authorizes DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical pharmaceutical supplier within the federal military medical supply chain, having received numerous delivery orders from the Defense Logistics Agency's Medical Supply Chain division across multiple therapeutic categories and product lines. The company's broader PPV-G GEN V contract, designated SPE2DR and awarded November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. This positioning enables the vendor to serve as a regional prime vendor contractor supplying specialized pharmaceuticals including oncology treatments, biologics, vaccines, and routine medications to support recurring medical supply needs of the Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FNMNB?
SPE2DB26FNMNB was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FNMNB worth?
The government has obligated $6,693 on SPE2DB26FNMNB.
Is contract SPE2DB26FNMNB an order under another contract?
Yes. SPE2DB26FNMNB is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNB competed?
The extent of competition for SPE2DB26FNMNB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award